Radiotherapy- Versus Surgery-based Treatment Strategy in High-risk Prostate Cancer.

IF 8.3 1区 医学 Q1 ONCOLOGY
Soumyajit Roy, Yilun Sun, James A Eastham, Martin Gleave, Christopher J D Wallis, Himisha A Beltran, Amar U Kishan, Angela Y Jia, Nicholas G Zaorsky, Himanshu Nagar, Jorge A Garcia, Eric J Small, Paul Nguyen, Gerhardt Attard, Rana R McKay, Oliver Sartor, Alejandro Berlin, Seth A Rosenthal, Susan Halabi, Randy Vince, Lee Ponsky, Scott C Morgan, Raquibul Hannan, Adam Raben, Mack Roach, Jeff M Michalski, Michael J Morris, Howard M Sandler, Daniel E Spratt
{"title":"Radiotherapy- Versus Surgery-based Treatment Strategy in High-risk Prostate Cancer.","authors":"Soumyajit Roy, Yilun Sun, James A Eastham, Martin Gleave, Christopher J D Wallis, Himisha A Beltran, Amar U Kishan, Angela Y Jia, Nicholas G Zaorsky, Himanshu Nagar, Jorge A Garcia, Eric J Small, Paul Nguyen, Gerhardt Attard, Rana R McKay, Oliver Sartor, Alejandro Berlin, Seth A Rosenthal, Susan Halabi, Randy Vince, Lee Ponsky, Scott C Morgan, Raquibul Hannan, Adam Raben, Mack Roach, Jeff M Michalski, Michael J Morris, Howard M Sandler, Daniel E Spratt","doi":"10.1016/j.euo.2025.06.009","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>Optimal management for high-risk prostate cancer is unclear. Using individual patient data from two contemporaneous North American cooperative group phase 3 randomized controlled trials (RCTs), we compared the outcomes of high-risk prostate cancer patients treated with radiotherapy-based and radical prostatectomy (RP)-based treatment strategies.</p><p><strong>Methods: </strong>Data were collected from newly diagnosed high-risk prostate cancer patients enrolled in NRG/RTOG 0521 who received radiotherapy-based treatment (2005-2009), and those enrolled in CALGB 90203 who received surgery-based treatment (2006-2015). Patients received radiotherapy plus 24 mo of androgen deprivation therapy (ADT) ± six cycles of adjuvant docetaxel versus RP with personalized postoperative therapy ± neoadjuvant six cycles of docetaxel and 18-24 wk of ADT. The primary objective was to compare the cumulative incidence of distant metastasis considering death as a competing event using the inverse probability of treatment weighting (IPTW).</p><p><strong>Key findings and limitations: </strong>Overall, 1290 patients (radiotherapy n = 557, RP n = 733) were included with similar follow-up (median 6.4 [interquartile range {IQR}: 5.6-6.9] yr and 6.4 [IQR: 4.7-8.5] yr, respectively). Patients who received surgery had generally more favorable prognostic features and were younger relative to those who received radiotherapy. After IPTW, the cumulative incidence of distant metastasis was significantly lower in patients who underwent radiotherapy-based compared with RP-based treatment (8-yr distant metastasis: 15% [95% confidence interval {CI} 9.3-21] vs 22% [95% CI 18-26]; adjusted subdistribution hazard ratio [sHR] 0.58 [95% CI 0.42-0.81]; p = 0.001). We did not find any significant difference in the incidence of deaths after distant metastasis (adjusted sHR 0.98 [95% CI 0.61-1.58]) between the two groups.</p><p><strong>Conclusions and clinical implications: </strong>High-risk prostate cancer patients enrolled in RCTs had a significantly lower incidence of distant metastasis with a radiotherapy-based treatment strategy than with an RP-based treatment strategy, while the risk of deaths after distant metastasis was similar in the two groups.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.3000,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European urology oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.euo.2025.06.009","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objective: Optimal management for high-risk prostate cancer is unclear. Using individual patient data from two contemporaneous North American cooperative group phase 3 randomized controlled trials (RCTs), we compared the outcomes of high-risk prostate cancer patients treated with radiotherapy-based and radical prostatectomy (RP)-based treatment strategies.

Methods: Data were collected from newly diagnosed high-risk prostate cancer patients enrolled in NRG/RTOG 0521 who received radiotherapy-based treatment (2005-2009), and those enrolled in CALGB 90203 who received surgery-based treatment (2006-2015). Patients received radiotherapy plus 24 mo of androgen deprivation therapy (ADT) ± six cycles of adjuvant docetaxel versus RP with personalized postoperative therapy ± neoadjuvant six cycles of docetaxel and 18-24 wk of ADT. The primary objective was to compare the cumulative incidence of distant metastasis considering death as a competing event using the inverse probability of treatment weighting (IPTW).

Key findings and limitations: Overall, 1290 patients (radiotherapy n = 557, RP n = 733) were included with similar follow-up (median 6.4 [interquartile range {IQR}: 5.6-6.9] yr and 6.4 [IQR: 4.7-8.5] yr, respectively). Patients who received surgery had generally more favorable prognostic features and were younger relative to those who received radiotherapy. After IPTW, the cumulative incidence of distant metastasis was significantly lower in patients who underwent radiotherapy-based compared with RP-based treatment (8-yr distant metastasis: 15% [95% confidence interval {CI} 9.3-21] vs 22% [95% CI 18-26]; adjusted subdistribution hazard ratio [sHR] 0.58 [95% CI 0.42-0.81]; p = 0.001). We did not find any significant difference in the incidence of deaths after distant metastasis (adjusted sHR 0.98 [95% CI 0.61-1.58]) between the two groups.

Conclusions and clinical implications: High-risk prostate cancer patients enrolled in RCTs had a significantly lower incidence of distant metastasis with a radiotherapy-based treatment strategy than with an RP-based treatment strategy, while the risk of deaths after distant metastasis was similar in the two groups.

高危前列腺癌的放疗与手术治疗策略。
背景与目的:高危前列腺癌的最佳治疗尚不清楚。我们使用来自两项同期北美合作组iii期随机对照试验(rct)的个体患者数据,比较了高危前列腺癌患者接受放疗和根治性前列腺切除术(RP)治疗策略的结果。方法:收集NRG/RTOG 0521纳入的2005-2009年放疗为主治疗的新诊断高危前列腺癌患者,以及CALGB 90203纳入的2006-2015年手术为主治疗的患者的数据。患者接受放疗+ 24个月雄激素剥夺治疗(ADT)±6个周期的辅助多西紫杉醇与RP配合个性化术后治疗±新辅助6个周期的多西紫杉醇和18-24周的ADT。主要目的是使用治疗加权逆概率(IPTW)比较考虑死亡作为竞争事件的远处转移的累积发生率。主要发现和局限性:总体而言,1290例患者(放疗n = 557, RP n = 733)纳入类似随访(中位数分别为6.4年[四分位数间距{IQR}: 5.6-6.9]年和6.4年[IQR: 4.7-8.5]年)。与接受放射治疗的患者相比,接受手术的患者通常具有更有利的预后特征,并且年龄更小。IPTW后,以放疗为基础的患者远端转移的累积发生率明显低于以rp为基础的患者(8年远端转移:15%[95%可信区间{CI} 9.3-21] vs 22% [95% CI 18-26];调整后的亚分布风险比[sHR] 0.58 [95% CI 0.42-0.81];p = 0.001)。我们没有发现两组之间远处转移后死亡发生率有显著差异(调整后sHR为0.98 [95% CI 0.61-1.58])。结论和临床意义:随机对照试验中纳入的高危前列腺癌患者,以放疗为基础的治疗策略远端转移的发生率明显低于以rp为基础的治疗策略,而两组远端转移后死亡的风险相似。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
15.50
自引率
2.40%
发文量
128
审稿时长
20 days
期刊介绍: Journal Name: European Urology Oncology Affiliation: Official Journal of the European Association of Urology Focus: First official publication of the EAU fully devoted to the study of genitourinary malignancies Aims to deliver high-quality research Content: Includes original articles, opinion piece editorials, and invited reviews Covers clinical, basic, and translational research Publication Frequency: Six times a year in electronic format
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信